2020 Alcohol Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Alcohol Addiction pipeline report presents a comprehensive overview of the research and development of Alcohol Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, 19 drugs in pre-clinical phase, 3 drugs in phase 1, ten drugs in phase 2, one drug in pre-registration phase
As of February 2020, the Alcohol Addiction pipeline remains robust with 36 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Alcohol Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 inhibitors; Alpha 1 adrenergic receptor antagonist; Alpha3 beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonists; Alpha4 Beta2 nAChR antagonist; CACNA2D1 protein modulators; CB1 and CB2 receptor agonist; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Ghrelin receptor inverse agonist; Glucocorticoid receptor II (GR) antagonists; Histamine H1 receptor antagonists; Histamine H3 receptor antagonist; Metabotropic glutamate receptor 5 (mGluR5) antagonists; NMDA receptor antagonist; Nociceptin opioid receptor (NOP) agonists; Opioid receptor antagonist; Orexin-1 receptor antagonist; PDE3 inhibitor; PDE4 inhibitor; PDE7 inhibitor; PKC_epsilon Inhibitors; Serotonin 2A receptor antagonists; Serotonin 3 receptor antagonists; Serotonin uptake inhibitors; Src-Family kinase inhibitors .
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Alcohol Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Alcohol Addiction pipeline drugs profiled in the report include- AD-04 (ondansetron), ANS-6637, NYX-783, gabapentin enacarbil , AP-202, AT-1001, nociceptin opioid receptor for Alcohol Addiction, saracatinib difumarate (AZD0530), BICX101, BICX102, BPI.3656B, CTDP-002, acamprosate calcium , Glucocorticoid receptor antagonist for Alcohol Dependance, CM-1212, ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders, odelepran (LY-2196044), KT-110 (cyproheptadine and prazosin), KNX100, ibudilast, GET73, Nezavist, MAP4343, 18-MC (18-Methoxycoronaridine), D15, OMS527, OS-440 (arbaclofen extended release), PF-05190457, SKL10406, Orexin OX1 Antagonists for Addiction, Tetracycline Analogs for Alcohol Use Disorder, Nalsyn, TNX-102, VMD-2202, cannabidiol (ZYN002), naltrexone hydrochloride
As of February 2020, the Alcohol Addiction pipeline remains robust with 36 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Alcohol Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 inhibitors; Alpha 1 adrenergic receptor antagonist; Alpha3 beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonists; Alpha4 Beta2 nAChR antagonist; CACNA2D1 protein modulators; CB1 and CB2 receptor agonist; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Ghrelin receptor inverse agonist; Glucocorticoid receptor II (GR) antagonists; Histamine H1 receptor antagonists; Histamine H3 receptor antagonist; Metabotropic glutamate receptor 5 (mGluR5) antagonists; NMDA receptor antagonist; Nociceptin opioid receptor (NOP) agonists; Opioid receptor antagonist; Orexin-1 receptor antagonist; PDE3 inhibitor; PDE4 inhibitor; PDE7 inhibitor; PKC_epsilon Inhibitors; Serotonin 2A receptor antagonists; Serotonin 3 receptor antagonists; Serotonin uptake inhibitors; Src-Family kinase inhibitors .
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Alcohol Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Alcohol Addiction development
- Alcohol Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Alcohol Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Alcohol Addiction pipeline candidates included
- Business overview and snapshot of all companies involved in Alcohol Addiction pipeline are included
- Latest market and pipeline developments are provided in the report
Alcohol Addiction pipeline drugs profiled in the report include- AD-04 (ondansetron), ANS-6637, NYX-783, gabapentin enacarbil , AP-202, AT-1001, nociceptin opioid receptor for Alcohol Addiction, saracatinib difumarate (AZD0530), BICX101, BICX102, BPI.3656B, CTDP-002, acamprosate calcium , Glucocorticoid receptor antagonist for Alcohol Dependance, CM-1212, ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders, odelepran (LY-2196044), KT-110 (cyproheptadine and prazosin), KNX100, ibudilast, GET73, Nezavist, MAP4343, 18-MC (18-Methoxycoronaridine), D15, OMS527, OS-440 (arbaclofen extended release), PF-05190457, SKL10406, Orexin OX1 Antagonists for Addiction, Tetracycline Analogs for Alcohol Use Disorder, Nalsyn, TNX-102, VMD-2202, cannabidiol (ZYN002), naltrexone hydrochloride
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Alcohol Addiction Condition
2.3 Alcohol Addiction Pipeline Snapshot, 2020
2.4 Companies investing in Alcohol Addiction pipeline therapeutics
2.5 Phase wise Alcohol Addiction Pipeline Candidates
2.6 Most Researched Mechanism of Action of Alcohol Addiction Pipeline Products
2.7 Route of Administration of Alcohol Addiction Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Adial Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Amygdala Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Arbor Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.5 Assuage Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Astraea Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.7 AstraZeneca Plc Overview, Contacts and ASD Pipeline Drugs
3.8 BioCorRx Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Bioprojet SCR Overview, Contacts and ASD Pipeline Drugs
3.10 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Confluence Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.12 Corcept Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Curemark LLC Overview, Contacts and ASD Pipeline Drugs
3.14 Dicerna Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.15 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.16 Kinnov Therapeutics SAS Overview, Contacts and ASD Pipeline Drugs
3.17 Kinoxis Therapeutics Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.18 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.19 Laboratorio Farmaceutico CT Srl Overview, Contacts and ASD Pipeline Drugs
3.20 Lohocla Research Corp Overview, Contacts and ASD Pipeline Drugs
3.21 Mapreg SAS Overview, Contacts and ASD Pipeline Drugs
3.22 Mind Medicine Inc Overview, Contacts and ASD Pipeline Drugs
3.23 Montisera Ltd Overview, Contacts and ASD Pipeline Drugs
3.24 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.25 Osmotica Pharmaceutical Corp Overview, Contacts and ASD Pipeline Drugs
3.26 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.27 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.28 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.29 South Plains Biotechnology Inc Overview, Contacts and ASD Pipeline Drugs
3.30 Syntropharma Ltd Overview, Contacts and ASD Pipeline Drugs
3.31 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
3.32 VM Discovery Inc Overview, Contacts and ASD Pipeline Drugs
3.33 Zynerba Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AD-04 (ondansetron) Drug Details
4.1.1 AD-04 (ondansetron) Current Status
4.1.2 AD-04 (ondansetron) Drug Overview
4.1.3 AD-04 (ondansetron) Mechanism of Action
4.1.4 AD-04 (ondansetron) Licensing/Collaboration Companies
4.1.5 AD-04 (ondansetron) Clinical Trials
4.2 ANS-6637 Drug Details
4.2.1 ANS-6637 Current Status
4.2.2 ANS-6637 Drug Overview
4.2.3 ANS-6637 Mechanism of Action
4.2.4 ANS-6637 Licensing/Collaboration Companies
4.2.5 ANS-6637 Clinical Trials
4.3 NYX-783 Drug Details
4.3.1 NYX-783 Current Status
4.3.2 NYX-783 Drug Overview
4.3.3 NYX-783 Mechanism of Action
4.3.4 NYX-783 Licensing/Collaboration Companies
4.3.5 NYX-783 Clinical Trials
4.4 gabapentin enacarbil Drug Details
4.4.1 gabapentin enacarbil Current Status
4.4.2 gabapentin enacarbil Drug Overview
4.4.3 gabapentin enacarbil Mechanism of Action
4.4.4 gabapentin enacarbil Licensing/Collaboration Companies
4.4.5 gabapentin enacarbil Clinical Trials
4.5 AP-202 Drug Details
4.5.1 AP-202 Current Status
4.5.2 AP-202 Drug Overview
4.5.3 AP-202 Mechanism of Action
4.5.4 AP-202 Licensing/Collaboration Companies
4.5.5 AP-202 Clinical Trials
4.6 AT-1001 Drug Details
4.6.1 AT-1001 Current Status
4.6.2 AT-1001 Drug Overview
4.6.3 AT-1001 Mechanism of Action
4.6.4 AT-1001 Licensing/Collaboration Companies
4.6.5 AT-1001 Clinical Trials
4.7 nociceptin opioid receptor for Alcohol Addiction Drug Details
4.7.1 nociceptin opioid receptor for Alcohol Addiction Current Status
4.7.2 nociceptin opioid receptor for Alcohol Addiction Drug Overview
4.7.3 nociceptin opioid receptor for Alcohol Addiction Mechanism of Action
4.7.4 nociceptin opioid receptor for Alcohol Addiction Licensing/Collaboration Companies
4.7.5 nociceptin opioid receptor for Alcohol Addiction Clinical Trials
4.8 saracatinib difumarate (AZD0530) Drug Details
4.8.1 saracatinib difumarate (AZD0530) Current Status
4.8.2 saracatinib difumarate (AZD0530) Drug Overview
4.8.3 saracatinib difumarate (AZD0530) Mechanism of Action
4.8.4 saracatinib difumarate (AZD0530) Licensing/Collaboration Companies
4.8.5 saracatinib difumarate (AZD0530) Clinical Trials
4.9 BICX101 Drug Details
4.9.1 BICX101 Current Status
4.9.2 BICX101 Drug Overview
4.9.3 BICX101 Mechanism of Action
4.9.4 BICX101 Licensing/Collaboration Companies
4.9.5 BICX101 Clinical Trials
4.10 BICX102 Drug Details
4.10.1 BICX102 Current Status
4.10.2 BICX102 Drug Overview
4.10.3 BICX102 Mechanism of Action
4.10.4 BICX102 Licensing/Collaboration Companies
4.10.5 BICX102 Clinical Trials
4.11 BPI.3656B Drug Details
4.11.1 BPI.3656B Current Status
4.11.2 BPI.3656B Drug Overview
4.11.3 BPI.3656B Mechanism of Action
4.11.4 BPI.3656B Licensing/Collaboration Companies
4.11.5 BPI.3656B Clinical Trials
4.12 CTDP-002 Drug Details
4.12.1 CTDP-002 Current Status
4.12.2 CTDP-002 Drug Overview
4.12.3 CTDP-002 Mechanism of Action
4.12.4 CTDP-002 Licensing/Collaboration Companies
4.12.5 CTDP-002 Clinical Trials
4.13 acamprosate calcium Drug Details
4.13.1 acamprosate calcium Current Status
4.13.2 acamprosate calcium Drug Overview
4.13.3 acamprosate calcium Mechanism of Action
4.13.4 acamprosate calcium Licensing/Collaboration Companies
4.13.5 acamprosate calcium Clinical Trials
4.14 Glucocorticoid receptor antagonist for Alcohol Dependance Drug Details
4.14.1 Glucocorticoid receptor antagonist for Alcohol Dependance Current Status
4.14.2 Glucocorticoid receptor antagonist for Alcohol Dependance Drug Overview
4.14.3 Glucocorticoid receptor antagonist for Alcohol Dependance Mechanism of Action
4.14.4 Glucocorticoid receptor antagonist for Alcohol Dependance Licensing/Collaboration Companies
4.14.5 Glucocorticoid receptor antagonist for Alcohol Dependance Clinical Trials
4.15 CM-1212 Drug Details
4.15.1 CM-1212 Current Status
4.15.2 CM-1212 Drug Overview
4.15.3 CM-1212 Mechanism of Action
4.15.4 CM-1212 Licensing/Collaboration Companies
4.15.5 CM-1212 Clinical Trials
4.16 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Drug Details
4.16.1 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Current Status
4.16.2 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Drug Overview
4.16.3 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Mechanism of Action
4.16.4 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Licensing/Collaboration Companies
4.16.5 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Clinical Trials
4.17 odelepran (LY-2196044) Drug Details
4.17.1 odelepran (LY-2196044) Current Status
4.17.2 odelepran (LY-2196044) Drug Overview
4.17.3 odelepran (LY-2196044) Mechanism of Action
4.17.4 odelepran (LY-2196044) Licensing/Collaboration Companies
4.17.5 odelepran (LY-2196044) Clinical Trials
4.18 KT-110 (cyproheptadine and prazosin) Drug Details
4.18.1 KT-110 (cyproheptadine and prazosin) Current Status
4.18.2 KT-110 (cyproheptadine and prazosin) Drug Overview
4.18.3 KT-110 (cyproheptadine and prazosin) Mechanism of Action
4.18.4 KT-110 (cyproheptadine and prazosin) Licensing/Collaboration Companies
4.18.5 KT-110 (cyproheptadine and prazosin) Clinical Trials
4.19 KNX100 Drug Details
4.19.1 KNX100 Current Status
4.19.2 KNX100 Drug Overview
4.19.3 KNX100 Mechanism of Action
4.19.4 KNX100 Licensing/Collaboration Companies
4.19.5 KNX100 Clinical Trials
4.20 ibudilast Drug Details
4.20.1 ibudilast Current Status
4.20.2 ibudilast Drug Overview
4.20.3 ibudilast Mechanism of Action
4.20.4 ibudilast Licensing/Collaboration Companies
4.20.5 ibudilast Clinical Trials
4.21 GET73 Drug Details
4.21.1 GET73 Current Status
4.21.2 GET73 Drug Overview
4.21.3 GET73 Mechanism of Action
4.21.4 GET73 Licensing/Collaboration Companies
4.21.5 GET73 Clinical Trials
4.22 Nezavist Drug Details
4.22.1 Nezavist Current Status
4.22.2 Nezavist Drug Overview
4.22.3 Nezavist Mechanism of Action
4.22.4 Nezavist Licensing/Collaboration Companies
4.22.5 Nezavist Clinical Trials
4.23 MAP4343 Drug Details
4.23.1 MAP4343 Current Status
4.23.2 MAP4343 Drug Overview
4.23.3 MAP4343 Mechanism of Action
4.23.4 MAP4343 Licensing/Collaboration Companies
4.23.5 MAP4343 Clinical Trials
4.24 18-MC (18-Methoxycoronaridine) Drug Details
4.24.1 18-MC (18-Methoxycoronaridine) Current Status
4.24.2 18-MC (18-Methoxycoronaridine) Drug Overview
4.24.3 18-MC (18-Methoxycoronaridine) Mechanism of Action
4.24.4 18-MC (18-Methoxycoronaridine) Licensing/Collaboration Companies
4.24.5 18-MC (18-Methoxycoronaridine) Clinical Trials
4.25 D15 Drug Details
4.25.1 D15 Current Status
4.25.2 D15 Drug Overview
4.25.3 D15 Mechanism of Action
4.25.4 D15 Licensing/Collaboration Companies
4.25.5 D15 Clinical Trials
4.26 OMS527 Drug Details
4.26.1 OMS527 Current Status
4.26.2 OMS527 Drug Overview
4.26.3 OMS527 Mechanism of Action
4.26.4 OMS527 Licensing/Collaboration Companies
4.26.5 OMS527 Clinical Trials
4.27 OS-440 (arbaclofen extended release) Drug Details
4.27.1 OS-440 (arbaclofen extended release) Current Status
4.27.2 OS-440 (arbaclofen extended release) Drug Overview
4.27.3 OS-440 (arbaclofen extended release) Mechanism of Action
4.27.4 OS-440 (arbaclofen extended release) Licensing/Collaboration Companies
4.27.5 OS-440 (arbaclofen extended release) Clinical Trials
4.28 PF-05190457 Drug Details
4.28.1 PF-05190457 Current Status
4.28.2 PF-05190457 Drug Overview
4.28.3 PF-05190457 Mechanism of Action
4.28.4 PF-05190457 Licensing/Collaboration Companies
4.28.5 PF-05190457 Clinical Trials
4.29 SKL10406 Drug Details
4.29.1 SKL10406 Current Status
4.29.2 SKL10406 Drug Overview
4.29.3 SKL10406 Mechanism of Action
4.29.4 SKL10406 Licensing/Collaboration Companies
4.29.5 SKL10406 Clinical Trials
4.30 Orexin OX1 Antagonists for Addiction Drug Details
4.30.1 Orexin OX1 Antagonists for Addiction Current Status
4.30.2 Orexin OX1 Antagonists for Addiction Drug Overview
4.30.3 Orexin OX1 Antagonists for Addiction Mechanism of Action
4.30.4 Orexin OX1 Antagonists for Addiction Licensing/Collaboration Companies
4.30.5 Orexin OX1 Antagonists for Addiction Clinical Trials
4.31 Tetracycline Analogs for Alcohol Use Disorder Drug Details
4.31.1 Tetracycline Analogs for Alcohol Use Disorder Current Status
4.31.2 Tetracycline Analogs for Alcohol Use Disorder Drug Overview
4.31.3 Tetracycline Analogs for Alcohol Use Disorder Mechanism of Action
4.31.4 Tetracycline Analogs for Alcohol Use Disorder Licensing/Collaboration Companies
4.31.5 Tetracycline Analogs for Alcohol Use Disorder Clinical Trials
4.32 Nalsyn Drug Details
4.32.1 Nalsyn Current Status
4.32.2 Nalsyn Drug Overview
4.32.3 Nalsyn Mechanism of Action
4.32.4 Nalsyn Licensing/Collaboration Companies
4.32.5 Nalsyn Clinical Trials
4.33 TNX-102 Drug Details
4.33.1 TNX-102 Current Status
4.33.2 TNX-102 Drug Overview
4.33.3 TNX-102 Mechanism of Action
4.33.4 TNX-102 Licensing/Collaboration Companies
4.33.5 TNX-102 Clinical Trials
4.34 VMD-2202 Drug Details
4.34.1 VMD-2202 Current Status
4.34.2 VMD-2202 Drug Overview
4.34.3 VMD-2202 Mechanism of Action
4.34.4 VMD-2202 Licensing/Collaboration Companies
4.34.5 VMD-2202 Clinical Trials
4.35 cannabidiol (ZYN002) Drug Details
4.35.1 cannabidiol (ZYN002) Current Status
4.35.2 cannabidiol (ZYN002) Drug Overview
4.35.3 cannabidiol (ZYN002) Mechanism of Action
4.35.4 cannabidiol (ZYN002) Licensing/Collaboration Companies
4.35.5 cannabidiol (ZYN002) Clinical Trials
4.36 naltrexone hydrochloride Drug Details
4.36.1 naltrexone hydrochloride Current Status
4.36.2 naltrexone hydrochloride Drug Overview
4.36.3 naltrexone hydrochloride Mechanism of Action
4.36.4 naltrexone hydrochloride Licensing/Collaboration Companies
4.36.5 naltrexone hydrochloride Clinical Trials
5. LATEST ALCOHOL ADDICTION PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Alcohol Addiction Condition
2.3 Alcohol Addiction Pipeline Snapshot, 2020
2.4 Companies investing in Alcohol Addiction pipeline therapeutics
2.5 Phase wise Alcohol Addiction Pipeline Candidates
2.6 Most Researched Mechanism of Action of Alcohol Addiction Pipeline Products
2.7 Route of Administration of Alcohol Addiction Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Adial Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Amygdala Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Arbor Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.5 Assuage Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Astraea Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.7 AstraZeneca Plc Overview, Contacts and ASD Pipeline Drugs
3.8 BioCorRx Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Bioprojet SCR Overview, Contacts and ASD Pipeline Drugs
3.10 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Confluence Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.12 Corcept Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Curemark LLC Overview, Contacts and ASD Pipeline Drugs
3.14 Dicerna Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.15 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.16 Kinnov Therapeutics SAS Overview, Contacts and ASD Pipeline Drugs
3.17 Kinoxis Therapeutics Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.18 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.19 Laboratorio Farmaceutico CT Srl Overview, Contacts and ASD Pipeline Drugs
3.20 Lohocla Research Corp Overview, Contacts and ASD Pipeline Drugs
3.21 Mapreg SAS Overview, Contacts and ASD Pipeline Drugs
3.22 Mind Medicine Inc Overview, Contacts and ASD Pipeline Drugs
3.23 Montisera Ltd Overview, Contacts and ASD Pipeline Drugs
3.24 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.25 Osmotica Pharmaceutical Corp Overview, Contacts and ASD Pipeline Drugs
3.26 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.27 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.28 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.29 South Plains Biotechnology Inc Overview, Contacts and ASD Pipeline Drugs
3.30 Syntropharma Ltd Overview, Contacts and ASD Pipeline Drugs
3.31 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
3.32 VM Discovery Inc Overview, Contacts and ASD Pipeline Drugs
3.33 Zynerba Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AD-04 (ondansetron) Drug Details
4.1.1 AD-04 (ondansetron) Current Status
4.1.2 AD-04 (ondansetron) Drug Overview
4.1.3 AD-04 (ondansetron) Mechanism of Action
4.1.4 AD-04 (ondansetron) Licensing/Collaboration Companies
4.1.5 AD-04 (ondansetron) Clinical Trials
4.2 ANS-6637 Drug Details
4.2.1 ANS-6637 Current Status
4.2.2 ANS-6637 Drug Overview
4.2.3 ANS-6637 Mechanism of Action
4.2.4 ANS-6637 Licensing/Collaboration Companies
4.2.5 ANS-6637 Clinical Trials
4.3 NYX-783 Drug Details
4.3.1 NYX-783 Current Status
4.3.2 NYX-783 Drug Overview
4.3.3 NYX-783 Mechanism of Action
4.3.4 NYX-783 Licensing/Collaboration Companies
4.3.5 NYX-783 Clinical Trials
4.4 gabapentin enacarbil Drug Details
4.4.1 gabapentin enacarbil Current Status
4.4.2 gabapentin enacarbil Drug Overview
4.4.3 gabapentin enacarbil Mechanism of Action
4.4.4 gabapentin enacarbil Licensing/Collaboration Companies
4.4.5 gabapentin enacarbil Clinical Trials
4.5 AP-202 Drug Details
4.5.1 AP-202 Current Status
4.5.2 AP-202 Drug Overview
4.5.3 AP-202 Mechanism of Action
4.5.4 AP-202 Licensing/Collaboration Companies
4.5.5 AP-202 Clinical Trials
4.6 AT-1001 Drug Details
4.6.1 AT-1001 Current Status
4.6.2 AT-1001 Drug Overview
4.6.3 AT-1001 Mechanism of Action
4.6.4 AT-1001 Licensing/Collaboration Companies
4.6.5 AT-1001 Clinical Trials
4.7 nociceptin opioid receptor for Alcohol Addiction Drug Details
4.7.1 nociceptin opioid receptor for Alcohol Addiction Current Status
4.7.2 nociceptin opioid receptor for Alcohol Addiction Drug Overview
4.7.3 nociceptin opioid receptor for Alcohol Addiction Mechanism of Action
4.7.4 nociceptin opioid receptor for Alcohol Addiction Licensing/Collaboration Companies
4.7.5 nociceptin opioid receptor for Alcohol Addiction Clinical Trials
4.8 saracatinib difumarate (AZD0530) Drug Details
4.8.1 saracatinib difumarate (AZD0530) Current Status
4.8.2 saracatinib difumarate (AZD0530) Drug Overview
4.8.3 saracatinib difumarate (AZD0530) Mechanism of Action
4.8.4 saracatinib difumarate (AZD0530) Licensing/Collaboration Companies
4.8.5 saracatinib difumarate (AZD0530) Clinical Trials
4.9 BICX101 Drug Details
4.9.1 BICX101 Current Status
4.9.2 BICX101 Drug Overview
4.9.3 BICX101 Mechanism of Action
4.9.4 BICX101 Licensing/Collaboration Companies
4.9.5 BICX101 Clinical Trials
4.10 BICX102 Drug Details
4.10.1 BICX102 Current Status
4.10.2 BICX102 Drug Overview
4.10.3 BICX102 Mechanism of Action
4.10.4 BICX102 Licensing/Collaboration Companies
4.10.5 BICX102 Clinical Trials
4.11 BPI.3656B Drug Details
4.11.1 BPI.3656B Current Status
4.11.2 BPI.3656B Drug Overview
4.11.3 BPI.3656B Mechanism of Action
4.11.4 BPI.3656B Licensing/Collaboration Companies
4.11.5 BPI.3656B Clinical Trials
4.12 CTDP-002 Drug Details
4.12.1 CTDP-002 Current Status
4.12.2 CTDP-002 Drug Overview
4.12.3 CTDP-002 Mechanism of Action
4.12.4 CTDP-002 Licensing/Collaboration Companies
4.12.5 CTDP-002 Clinical Trials
4.13 acamprosate calcium Drug Details
4.13.1 acamprosate calcium Current Status
4.13.2 acamprosate calcium Drug Overview
4.13.3 acamprosate calcium Mechanism of Action
4.13.4 acamprosate calcium Licensing/Collaboration Companies
4.13.5 acamprosate calcium Clinical Trials
4.14 Glucocorticoid receptor antagonist for Alcohol Dependance Drug Details
4.14.1 Glucocorticoid receptor antagonist for Alcohol Dependance Current Status
4.14.2 Glucocorticoid receptor antagonist for Alcohol Dependance Drug Overview
4.14.3 Glucocorticoid receptor antagonist for Alcohol Dependance Mechanism of Action
4.14.4 Glucocorticoid receptor antagonist for Alcohol Dependance Licensing/Collaboration Companies
4.14.5 Glucocorticoid receptor antagonist for Alcohol Dependance Clinical Trials
4.15 CM-1212 Drug Details
4.15.1 CM-1212 Current Status
4.15.2 CM-1212 Drug Overview
4.15.3 CM-1212 Mechanism of Action
4.15.4 CM-1212 Licensing/Collaboration Companies
4.15.5 CM-1212 Clinical Trials
4.16 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Drug Details
4.16.1 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Current Status
4.16.2 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Drug Overview
4.16.3 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Mechanism of Action
4.16.4 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Licensing/Collaboration Companies
4.16.5 ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders Clinical Trials
4.17 odelepran (LY-2196044) Drug Details
4.17.1 odelepran (LY-2196044) Current Status
4.17.2 odelepran (LY-2196044) Drug Overview
4.17.3 odelepran (LY-2196044) Mechanism of Action
4.17.4 odelepran (LY-2196044) Licensing/Collaboration Companies
4.17.5 odelepran (LY-2196044) Clinical Trials
4.18 KT-110 (cyproheptadine and prazosin) Drug Details
4.18.1 KT-110 (cyproheptadine and prazosin) Current Status
4.18.2 KT-110 (cyproheptadine and prazosin) Drug Overview
4.18.3 KT-110 (cyproheptadine and prazosin) Mechanism of Action
4.18.4 KT-110 (cyproheptadine and prazosin) Licensing/Collaboration Companies
4.18.5 KT-110 (cyproheptadine and prazosin) Clinical Trials
4.19 KNX100 Drug Details
4.19.1 KNX100 Current Status
4.19.2 KNX100 Drug Overview
4.19.3 KNX100 Mechanism of Action
4.19.4 KNX100 Licensing/Collaboration Companies
4.19.5 KNX100 Clinical Trials
4.20 ibudilast Drug Details
4.20.1 ibudilast Current Status
4.20.2 ibudilast Drug Overview
4.20.3 ibudilast Mechanism of Action
4.20.4 ibudilast Licensing/Collaboration Companies
4.20.5 ibudilast Clinical Trials
4.21 GET73 Drug Details
4.21.1 GET73 Current Status
4.21.2 GET73 Drug Overview
4.21.3 GET73 Mechanism of Action
4.21.4 GET73 Licensing/Collaboration Companies
4.21.5 GET73 Clinical Trials
4.22 Nezavist Drug Details
4.22.1 Nezavist Current Status
4.22.2 Nezavist Drug Overview
4.22.3 Nezavist Mechanism of Action
4.22.4 Nezavist Licensing/Collaboration Companies
4.22.5 Nezavist Clinical Trials
4.23 MAP4343 Drug Details
4.23.1 MAP4343 Current Status
4.23.2 MAP4343 Drug Overview
4.23.3 MAP4343 Mechanism of Action
4.23.4 MAP4343 Licensing/Collaboration Companies
4.23.5 MAP4343 Clinical Trials
4.24 18-MC (18-Methoxycoronaridine) Drug Details
4.24.1 18-MC (18-Methoxycoronaridine) Current Status
4.24.2 18-MC (18-Methoxycoronaridine) Drug Overview
4.24.3 18-MC (18-Methoxycoronaridine) Mechanism of Action
4.24.4 18-MC (18-Methoxycoronaridine) Licensing/Collaboration Companies
4.24.5 18-MC (18-Methoxycoronaridine) Clinical Trials
4.25 D15 Drug Details
4.25.1 D15 Current Status
4.25.2 D15 Drug Overview
4.25.3 D15 Mechanism of Action
4.25.4 D15 Licensing/Collaboration Companies
4.25.5 D15 Clinical Trials
4.26 OMS527 Drug Details
4.26.1 OMS527 Current Status
4.26.2 OMS527 Drug Overview
4.26.3 OMS527 Mechanism of Action
4.26.4 OMS527 Licensing/Collaboration Companies
4.26.5 OMS527 Clinical Trials
4.27 OS-440 (arbaclofen extended release) Drug Details
4.27.1 OS-440 (arbaclofen extended release) Current Status
4.27.2 OS-440 (arbaclofen extended release) Drug Overview
4.27.3 OS-440 (arbaclofen extended release) Mechanism of Action
4.27.4 OS-440 (arbaclofen extended release) Licensing/Collaboration Companies
4.27.5 OS-440 (arbaclofen extended release) Clinical Trials
4.28 PF-05190457 Drug Details
4.28.1 PF-05190457 Current Status
4.28.2 PF-05190457 Drug Overview
4.28.3 PF-05190457 Mechanism of Action
4.28.4 PF-05190457 Licensing/Collaboration Companies
4.28.5 PF-05190457 Clinical Trials
4.29 SKL10406 Drug Details
4.29.1 SKL10406 Current Status
4.29.2 SKL10406 Drug Overview
4.29.3 SKL10406 Mechanism of Action
4.29.4 SKL10406 Licensing/Collaboration Companies
4.29.5 SKL10406 Clinical Trials
4.30 Orexin OX1 Antagonists for Addiction Drug Details
4.30.1 Orexin OX1 Antagonists for Addiction Current Status
4.30.2 Orexin OX1 Antagonists for Addiction Drug Overview
4.30.3 Orexin OX1 Antagonists for Addiction Mechanism of Action
4.30.4 Orexin OX1 Antagonists for Addiction Licensing/Collaboration Companies
4.30.5 Orexin OX1 Antagonists for Addiction Clinical Trials
4.31 Tetracycline Analogs for Alcohol Use Disorder Drug Details
4.31.1 Tetracycline Analogs for Alcohol Use Disorder Current Status
4.31.2 Tetracycline Analogs for Alcohol Use Disorder Drug Overview
4.31.3 Tetracycline Analogs for Alcohol Use Disorder Mechanism of Action
4.31.4 Tetracycline Analogs for Alcohol Use Disorder Licensing/Collaboration Companies
4.31.5 Tetracycline Analogs for Alcohol Use Disorder Clinical Trials
4.32 Nalsyn Drug Details
4.32.1 Nalsyn Current Status
4.32.2 Nalsyn Drug Overview
4.32.3 Nalsyn Mechanism of Action
4.32.4 Nalsyn Licensing/Collaboration Companies
4.32.5 Nalsyn Clinical Trials
4.33 TNX-102 Drug Details
4.33.1 TNX-102 Current Status
4.33.2 TNX-102 Drug Overview
4.33.3 TNX-102 Mechanism of Action
4.33.4 TNX-102 Licensing/Collaboration Companies
4.33.5 TNX-102 Clinical Trials
4.34 VMD-2202 Drug Details
4.34.1 VMD-2202 Current Status
4.34.2 VMD-2202 Drug Overview
4.34.3 VMD-2202 Mechanism of Action
4.34.4 VMD-2202 Licensing/Collaboration Companies
4.34.5 VMD-2202 Clinical Trials
4.35 cannabidiol (ZYN002) Drug Details
4.35.1 cannabidiol (ZYN002) Current Status
4.35.2 cannabidiol (ZYN002) Drug Overview
4.35.3 cannabidiol (ZYN002) Mechanism of Action
4.35.4 cannabidiol (ZYN002) Licensing/Collaboration Companies
4.35.5 cannabidiol (ZYN002) Clinical Trials
4.36 naltrexone hydrochloride Drug Details
4.36.1 naltrexone hydrochloride Current Status
4.36.2 naltrexone hydrochloride Drug Overview
4.36.3 naltrexone hydrochloride Mechanism of Action
4.36.4 naltrexone hydrochloride Licensing/Collaboration Companies
4.36.5 naltrexone hydrochloride Clinical Trials
5. LATEST ALCOHOL ADDICTION PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
